A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

##STR00001##

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cylohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cylohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.

The invention relates to a compound of formula (I), characterised by the characteristic signals in the X-ray diffraction powder pattern measured with Cu Kalpha radiation (0.154 nm) at a 2-theta angle of 15.0 and 22.7 with a high intensity, and of 5.0, 11.3, 18.9, 20.8, 21.6 and 23.6 with a medium intensity, as well as to a method for producing the compound of formula (I) by reacting at least one isophthalic acid diester of formula (II) where R1 and R2 are the same or different and stand for an aliphatic group, with two equivalents 4-amino-2,2,6,6-tetramethylpiperidine, in the presence of at least one catalyst from the group of metal alcoholates and at a reaction temperature of between 50 and 150 C.

The invention relates to a compound of formula (I), characterised by the characteristic signals in the X-ray diffraction powder pattern measured with Cu Kalpha radiation (0.154 nm) at a 2-theta angle of 15.0 and 22.7 with a high intensity, and of 5.0, 11.3, 18.9, 20.8, 21.6 and 23.6 with a medium intensity, as well as to a method for producing the compound of formula (I) by reacting at least one isophthalic acid diester of formula (II) where R1 and R2 are the same or different and stand for an aliphatic group, with two equivalents 4-amino-2,2,6,6-tetramethylpiperidine, in the presence of at least one catalyst from the group of metal alcoholates and at a reaction temperature of between 50 and 150 C.

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

Compounds of the formula I ##STR00001##
in which R.sup.1, R.sup.4, R.sup.6, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in claim 1,
are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Compounds of the formula I ##STR00001##
in which R.sup.1, R.sup.4, R.sup.6, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in claim 1,
are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.